Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: SullyInFL who wrote (4133)	2/13/2016 9:38:50 AM
From: Vidpok1	Read Replies (1) \| Respond to of 4474

Jaybe's last post is the latest indication that the potential for Ponatinib to greatly expand its current limited approval remains a strong possibility in the future. This will apparently take a long time and a large investment but for the purposes of assigning value in a buyout agreement this latest affirmation of ponatinib's future potential is very good news indeed. Those who continue to relegate Ponatinib to its current third line status might do well to read the articles which continue to be written about the multiple indications which remain to be explored for this drug which is only beginning to be understood. Additionally, a large pharma will have the means and incentive to argue that Ponatinib should be approved for second line use given the fact that the other second line drugs share similar toxicity BUT are nowhere near as effective. All of this will lead to a buyout value in excess of the numbers being thrown out on Ihub by those with a very obvious agenda based on trying to instill fear, doubt, and uncertainty. Not to mention the very obvious fact that Ariad's share price has been and will continue to be totally linked to the sector performance except somewhat better in fact given Ariad's beta of about 1.7 relative to the IBB. Thanks Jaybe for pointing out articles that give the lie to those who post incessantly negative comments about ponatinib and the company in general.